Contact Merck Customer Service
Merck Phone Numbers and Emails
Toll-Free Number:
-
(800) 444-2080Products and services and adverse event reporting
Customer Service:
-
+1 514 428 7920Canada Location
Headquarters:
-
(908) 740-4000
Investors:
-
(908) 740-1468
Merck Emails:
Merck Contact Information
Merck Website:
Merck Help Center:
Corporate Office Address:
Other Info (opening hours):
Hours:
Monday – Friday: 8:30 am – 5:30 pm ET
Merck Animal Health headquarters:
2 Giralda Farms,
Madison,
New Jersey 07940
Summary of Merck Customer Service Calls
CALLS
DURATION
RESOLVED
Top Reasons of Customers Calls
Consumers Call the Most From
Why Do People Call Merck Customer Service?
Request for Information Question:
- “Molnupiravir question”
- “Want to plasce an order for a product and need information on the lead time and delivery date”
- “Looking for a Janumet coupon”
Payments and Charges Question:
- “Set up direct deposit”
Account Question:
- “My account got locked”
Staff Question:
- “Customer service”
Product/ Service Question:
- “Pt reports damaged shipment”
Other Question:
- “PF closure.”
- “Column coa”
- “I was missing a pill I. My molnupiravir Covid 19 medicine. Will that lesson the effect of the medicine?”
About
Merck & Co., Inc., is a research-intensive biotechnology company. It's also known as Merck Sharp & Dohme. Founded in 1891, Merck focuses on the development of medicines and vaccines to prevent a number of challenging diseases including cancer, infectious diseases, such as HIV and Ebola, and emerging animal diseases. Merck & Co owns a wide range of brands including but not limited to Januvia, Zetia, Remicade, Gardasil, and Keytruda. Starting in March 2020, Merck began responding to the global COVID-19 challenge. Currently, it has a pipeline of investigational medicines and vaccines designed to address the COVID-19 pandemic. In collaboration with Ridgeback Bio, they developed a novel, oral antiviral candidate MK-4482. With IAVI, a non-profit scientific organization, Merck generated an rVSV vector-based vaccine V590. The Pase 2/3 of the MK-4482 COVID-19 vaccine candidate was launched in October 2020. The first patient was dosed in the Phase 1 study of the V590 vaccine in November 2020. Merck also announced the planned acquisition of OncoImmune for further development of CD24Fc, a vaccine candidate to treat people challenged with severe COVID-19. Many biotechnology companies including Clover and GlaxoSmithKline are leveraging their scientific expertise to develop a COVID-19 vaccine candidate that elicits a protective and long-lasting immune response.
Merck is ranked 58 out of 1212 in Insurance category
Compare Merck To
Companies are selected automatically by the algorithm. A company's rating is calculated using a mathematical algorithm that evaluates the information in your profile. The algorithm parameters are: user's rating, number of resolved issues, number of company's responses etc. The algorithm is subject to change in future.
